Mounjaro is an innovative treatment that mimics the combined effects of the hormones GLP-1 and GIP. This makes it particularly effective in weight loss and improving blood sugar control, especially in patients with type 2 diabetes. In clinical trials, Mounjaro has shown to be superior in reducing body weight compared to other GLP-1 agonists. For more information about Mounjaro, visit our detail page.
Comparison with Saxenda and Wegovy: while Saxenda and Wegovy also being GLP-1 receptor agonists, Mounjaro has the additional effect of GIP, which contributes to better weight loss results. Wegovy, which also contains semaglutide, should be gradually increased to 2.4 mg per week. See more about this on our page about Wegovy.
Zepbound vs. Mounjaro: Both share the same active ingredient, tirzepatide, but Zepbound is currently not available in the Netherlands. This makes Mounjaro the go-to choice for patients who benefit from this combination of GLP-1 and GIP agonist properties.
Still have questions?
Våra kundtjänsttider är:
Måndag - fredag
08:30 - 18:00
Chat och e-post
Lördag - söndag
Chat och e-post besvaras på måndagen
Chatta med oss eller skicka ett e-postmeddelande till support@goodweigh.nl